Ixico plc logo

Ixico plc (PHYOF)

Market Closed
1 Jun, 13:30
OTC PINK OTC PINK
$
0. 0700
0
0%
$
6.51M Market Cap
- P/E Ratio
- Div Yield
1,000 Volume
- Eps
$ 0.07
Previous Close
Add Transaction
Day Range
0.07 0.07
Year Range
0.07 0.15
Want to track PHYOF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

PHYOF closed Monday higher at $0.07, an increase of 0% from Friday's close, completing a monthly increase of 0% or $0. Over the past 12 months, PHYOF stock gained 0%.
PHYOF is not paying dividends to its shareholders.
The last earnings report, released on May 26, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Ixico plc has completed 4 stock splits, with the recent split occurring on Nov 27, 2013.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on LSE (GBX).

PHYOF Chart

People also search for

Nuo Therapeutics Inc.
$ 1.06
-0.93%
VicapSys Life Sciences Inc.
$ 1.46
0%
Healixa Inc.
$ 0.05
0%
Medigene AG
$ 2.59
0%
Quantumzyme Corp.
$ 0.8
+33.33%

Ixico plc (PHYOF) FAQ

What is the stock price today?

The current price is $0.0700.

On which exchange is it traded?

Ixico plc is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is PHYOF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 6.51M.

Has Ixico plc ever had a stock split?

Ixico plc had 4 splits and the recent split was on Nov 27, 2013.

Ixico plc Profile

Biotechnology Industry
Healthcare Sector
Bram Goorden CEO
OTC PINK Exchange
GB00BFXR4C20 ISIN
GB Country
81 Employees
- Last Dividend
4 Sep 2013 Last Split
- IPO Date

Overview

IXICO plc specializes in providing comprehensive data analytics services tailored to meet the needs of the biopharmaceutical industry across various regions including the United Kingdom, Switzerland, the Netherlands, Ireland, other parts of Europe, and the United States. Founded in 1995 and headquartered in London, the company has carved a niche in offering advanced solutions for the collection, analysis, management, and reporting of data accumulated during clinical studies. With a strong emphasis on neurological disorders, IXICO plc has developed a profound expertise in therapeutic areas such as Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, as well as orphan and rare diseases. Through its innovative technologies and services, the company aims to assist in the acceleration of drug development processes and improve clinical trial outcomes.

Products and Services

- Assessa: An online digital platform specially designed for clinics. Assessa simplifies the process of neurological assessments by providing a centralized platform where clinical data can be efficiently managed and analyzed. Its user-friendly interface and robust back-end make it an indispensable tool for clinicians engaged in neurodegenerative disease management.

- TrialTracker: A comprehensive platform that streamlines the imaging workflow in clinical trials. From image upload and quality control to reading/analysis, reporting, and data transfer, TrialTracker offers a seamless experience. It is engineered to handle the complexities of imaging data management, making it a key solution for biopharmaceutical companies focused on developing treatments for neurological conditions.

- Drug Development Analytics: IXICO provides cutting-edge analytics services that support the drug development lifecycle. By leveraging data, IXICO helps to reduce risk, optimize outcomes, and enhance the understanding of drug efficacy and safety. These services are crucial for making informed decisions throughout the drug development process.

- Imaging Operation Services: These services cater to the operational needs of clinical trials that require medical imaging. IXICO ensures that imaging site set-up, management, and data handling are conducted with the highest standards of quality and efficiency, thereby facilitating smoother study execution.

- Post Marketing Surveillance: After a drug has been launched, it's critical to monitor its performance and safety in the real world. IXICO offers post-marketing surveillance services to help biopharmaceutical companies collect and analyze this vital data, ensuring ongoing compliance and patient safety.

- Consultancy Services: With years of industry experience, IXICO offers consultancy services that provide strategic insights and practical guidance for clinical trial design, regulatory pathways, and other critical aspects of drug development. These services are tailored to meet the unique needs of each client, ensuring best practices are applied to their projects.

- End-to-End Services: Covering everything from trial design and consultation to project management, imaging site management, data management, analysis, and regulatory support, IXICO offers comprehensive end-to-end services. This all-inclusive approach ensures that clinical trials are executed efficiently, with a focus on quality and regulatory compliance.

Contact Information

Address: Griffin Court
Phone: 44 20 3763 7499